Related Experiment Video

Updated: Sep 26, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer

Chengfeng Wang1, Diling Pan2

  • 1Department of Gastrointestinal Surgery, Affiliated people's Hospital (Fujian Provincial People's Hospital), Fujian University of Traditional Chinese Medicine, Fujian, China.

Journal of Clinical Laboratory Analysis
|April 18, 2022
PubMed
Abstract

Insights

Colorectal cancer patient survival is linked to specific gene mutations in B-Raf Proto-Oncogene (BRAF), KRAS Proto-Oncogene (KRAS), and Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA). These mutation patterns, not clinicopathological features, predict patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) is characterized by aberrant gene expression and signaling pathways.
  • Mutations in B-Raf Proto-Oncogene (BRAF), KRAS Proto-Oncogene (KRAS), and Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) are common in CRC.

Purpose of the Study:

  • To investigate the relationship between BRAF, KRAS, and PIK3CA mutations and the clinicopathologic features and prognosis of colorectal cancer patients.

Main Methods:

  • 150 colorectal cancer patients were grouped by BRAF, KRAS, and PIK3CA mutation patterns.
  • Chi-square test analyzed associations with clinicopathological factors.
  • Kaplan-Meier curves and Cox regression assessed survival impact.

Main Results:

  • BRAF, KRAS, and PIK3CA mutations showed no association with age, sex, or alcoholism.
  • Overall survival rate was significantly associated with gene mutation patterns.
  • Patients with KRAS+/PIK3CA-/BRAF- or KRAS-/PIK3CA-/BRAF+ mutations had better prognoses than KRAS+/PIK3CA+/BRAF- patients.

Conclusions:

  • BRAF, KRAS, and PIK3CA mutant patterns are independent of general and clinicopathological features in colorectal cancer.
  • Gene mutation patterns serve as significant prognostic factors for colorectal cancer.
Keywords:
BRAF mutationKRAS mutationPIK3CA mutationcolorectal cancerprognostic analysis

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.3K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K